The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification
Abstract Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the e...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-03-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-024-03261-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850284673019674624 |
|---|---|
| author | Lijuan Weng Jianliang Zhou Shenchao Guo Nong Xu Ruishuang Ma |
| author_facet | Lijuan Weng Jianliang Zhou Shenchao Guo Nong Xu Ruishuang Ma |
| author_sort | Lijuan Weng |
| collection | DOAJ |
| description | Abstract Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected therapeutic effects due to the lack of clear molecular targets. Based on genomics, transcriptomics and metabolomics, the multi-omics analysis further clarifies TNBC subtyping, which provides a greater understanding of tumour heterogeneity and targeted therapy sensitivity. For instance, the luminal androgen receptor subtype (LAR) exhibits responsiveness to anti-AR therapy, and the basal-like immune-suppressed subtype (BLIS) tends to benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) and anti-angiogenic therapy. The efficacy of multi-dimensional combination therapy holds immense importance in guiding personalized and precision medicine for TNBC. This review offers a systematic overview of recent FuDan TNBC molecular subtyping and its role in the instruction of clinical precision therapy. |
| format | Article |
| id | doaj-art-e784845718ea442b9b595d15f6312555 |
| institution | OA Journals |
| issn | 1475-2867 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj-art-e784845718ea442b9b595d15f63125552025-08-20T01:47:30ZengBMCCancer Cell International1475-28672024-03-0124111110.1186/s12935-024-03261-0The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classificationLijuan Weng0Jianliang Zhou1Shenchao Guo2Nong Xu3Ruishuang Ma4Department of Medical Oncology, The First Affiliated Hospital of Zhejiang UniversityDepartment of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Ningbo UniversityDepartment of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Ningbo UniversityDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang UniversityDepartment of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Ningbo UniversityAbstract Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected therapeutic effects due to the lack of clear molecular targets. Based on genomics, transcriptomics and metabolomics, the multi-omics analysis further clarifies TNBC subtyping, which provides a greater understanding of tumour heterogeneity and targeted therapy sensitivity. For instance, the luminal androgen receptor subtype (LAR) exhibits responsiveness to anti-AR therapy, and the basal-like immune-suppressed subtype (BLIS) tends to benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) and anti-angiogenic therapy. The efficacy of multi-dimensional combination therapy holds immense importance in guiding personalized and precision medicine for TNBC. This review offers a systematic overview of recent FuDan TNBC molecular subtyping and its role in the instruction of clinical precision therapy.https://doi.org/10.1186/s12935-024-03261-0Triple-negative breast cancerMolecular subtypingPrecision medicine |
| spellingShingle | Lijuan Weng Jianliang Zhou Shenchao Guo Nong Xu Ruishuang Ma The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification Cancer Cell International Triple-negative breast cancer Molecular subtyping Precision medicine |
| title | The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification |
| title_full | The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification |
| title_fullStr | The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification |
| title_full_unstemmed | The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification |
| title_short | The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification |
| title_sort | molecular subtyping and precision medicine in triple negative breast cancer based on fudan tnbc classification |
| topic | Triple-negative breast cancer Molecular subtyping Precision medicine |
| url | https://doi.org/10.1186/s12935-024-03261-0 |
| work_keys_str_mv | AT lijuanweng themolecularsubtypingandprecisionmedicineintriplenegativebreastcancerbasedonfudantnbcclassification AT jianliangzhou themolecularsubtypingandprecisionmedicineintriplenegativebreastcancerbasedonfudantnbcclassification AT shenchaoguo themolecularsubtypingandprecisionmedicineintriplenegativebreastcancerbasedonfudantnbcclassification AT nongxu themolecularsubtypingandprecisionmedicineintriplenegativebreastcancerbasedonfudantnbcclassification AT ruishuangma themolecularsubtypingandprecisionmedicineintriplenegativebreastcancerbasedonfudantnbcclassification AT lijuanweng molecularsubtypingandprecisionmedicineintriplenegativebreastcancerbasedonfudantnbcclassification AT jianliangzhou molecularsubtypingandprecisionmedicineintriplenegativebreastcancerbasedonfudantnbcclassification AT shenchaoguo molecularsubtypingandprecisionmedicineintriplenegativebreastcancerbasedonfudantnbcclassification AT nongxu molecularsubtypingandprecisionmedicineintriplenegativebreastcancerbasedonfudantnbcclassification AT ruishuangma molecularsubtypingandprecisionmedicineintriplenegativebreastcancerbasedonfudantnbcclassification |